SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

In patients with symptom resolution of C. difficile infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection. The observed safety profile of SER-109 was similar to that of placebo. (Funded by Seres Therapeutics; ECOSPOR III ClinicalTrials.gov number, NCT03183128.). Read more at: https://pubmed.ncbi.nlm.nih.gov/35045228/